Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression

Roberto Ferrarese,1 Griffith R. Harsh IV,2 Ajay K. Yadav,3 Eva Bug,1 Daniel Maticzka,4 Wilfried Reichardt,5 Stephen M. Dombrowski,9 Tyler E. Miller,7 Anie P. Masilamani,1 Fangping Dai,1 Hyunsoo Kim,8 Michael Hadler,1 Denise M. Scholtens,9 Irene L.Y. Yu,1 Jürgen Beck,1 Vinodh Srinivasasainagendra,10 Fabrizio Costa,8 Nicoleta Baxan,8 Dietmar Pfeifer,11 Dominik von Elverfeldt,5 Rolf Backofen,4 Astrid Weyerbrock,1 Christine W. Duarte,12 Xiaolin He,13 Marco Prinz,14 James P. Chandler,15 Hannes Vogel,16 Arnab Chakravarti,17 Jeremy N. Rich,7 Maria S. Carro,1 and Markus Bredel1,2,18

Department of Neurosurgery, Neurocenter, and Comprehensive Cancer Center, University of Freiburg, Freiburg, Germany. 2Department of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA. 3Dr. B.R. Ambedkar Center for Biomedical Research, University of Delhi, Delhi, India. 4Department of Computer Science and BIOSS Centre for Biological Signalling Studies, and 5Medical Physics, Department of Radiology, and Comprehensive Cancer Center, University of Freiburg, Freiburg, Germany. 6Department of Neurological Surgery, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. 7Department of Preventive Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA. 8Department of Radiation Oncology, UAB Comprehensive Cancer Center, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA. 9Department of Hematology and Oncology, and Comprehensive Cancer Center, University of Freiburg, Freiburg, Germany. 10Department for Outcomes Research and Evaluation, Maine Medical Center Research Institute, Scarborough, Maine, USA. 11Department of Molecular Pharmacology and Biological Chemistry, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. 12Department of Preventive Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA. 13Department of Molecular Pharmacology and Biological Chemistry, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. 14Department of Neuropathology and BIOSS Centre for Biological Signalling Studies, University of Freiburg, Freiburg, Germany. 15Department of Neurological Surgery, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. 16Department of Neuropathology, Stanford University School of Medicine, Stanford, California, USA. 17Department of Radiation Oncology, OSU Comprehensive Cancer Center and Richard L. Solove Research Institute, Ohio State University, Columbus, Ohio, USA. 18Department of Radiation Oncology, UAB Comprehensive Cancer Center, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.

Tissue-specific alternative splicing is critical for the emergence of tissue identity during development, yet the role of this process in malignant transformation is undefined. Tissue-specific splicing involves evolutionarily conserved, alternative exons that represent only a minority of the total alternative exons identified. Many of these conserved exons have functional features that influence signaling pathways to profound biological effect. Here, we determined that lineage-specific splicing of a brain-enriched cassette exon in the membrane-binding tumor suppressor annexin A7 (ANXA7) diminishes endosomal targeting of the EGFR oncoprotein, consequently enhancing EGFR signaling during brain tumor progression. ANXA7 exon splicing was mediated by the ribonucleoprotein PTBP1, which is normally repressed during neuronal development. PTBP1 was highly expressed in glioblastomas due to loss of a brain-enriched microRNA (miR-124) and to PTBP1 amplification. The alternative ANXA7 splicing trait was present in precursor cells, suggesting that glioblastoma cells inherit the trait from a potential tumor-initiating ancestor and that these cells exploit this trait through accumulation of mutations that enhance EGFR signaling. Our data illustrate that lineage-specific splicing of a tissue-regulated alternative exon in a constituent of an oncogenic pathway eliminates tumor suppressor functions and promotes glioblastoma progression. This paradigm may offer a general model as to how tissue-specific regulatory mechanisms can reprogram normal developmental processes into oncogenic ones.

Introduction
Glioblastoma multiforme is a complex genomic disease in which multiple signaling pathways are disrupted by recurrent mutations (1–4). Almost all glioblastomas exhibit excessive activation of the EGFR pathway, often elicited by amplification or activating mutations of the EGFR oncogene (5) or by additional or alternative genetic mechanisms, leading to deregulation of EGFR signaling (6–8). We have previously shown that loss of the tumor suppressor annexin A7 (ANXA7), a membrane-binding protein with diverse properties, is associated with deregulation of EGFR signaling and glioblastoma patient prognosis (2, 8).

Alternative splicing is involved in many cellular and developmental processes. Splicing of pre-mRNA is a major mechanism for the enhancement of transcriptome and proteome diversity, functional versatility, and regulatory complexity (9, 10). The type of alternative splicing that contributes most to phenotypic complexity in higher eukaryotes involves the skipping of alternative

Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J Clin Invest. 2014;124(7):2861–2876. doi:10.1172/JCI68836.
Reference
cassette exons, which by definition are internal exons that are differentially included in the various splicing isoforms of a gene (11). Alternative splicing of pre-mRNA can promote cancer formation by generating proteins that are truncated or missing domains and consequently have altered function (12–18). There is strong evidence that aberrant splice isoforms are involved in the pathogenesis of glioblastoma and can function as oncogenic drivers in these tumors (19, 20). For example, the EGFR oncogene is a frequent target of aberrant splicing in glioblastoma as a consequence of deletion-rearrangement of the amplified gene (21, 22).

There is increasing evidence that spatiotemporal generation of splicing variants plays an important role in regulating tissue-specific identity and dynamics (23, 24). Tissue-specific splicing involves alternative exons that are evolutionarily conserved and that may possess related functions, yet their common functional features are just starting to be understood (11, 23, 24). Understanding of the role of alternative exons in human cancer has been limited to evidence that splicing of selected genes is specifically modified during tumor development to allow the expression of isoforms that promote cancer cell survival (25). However, little is known about the contribution of tissue-regulated alternative exons to tumorigenesis in a tissue-specific context. Tissue-specific exons play crucial roles in attaining and maintaining tissue identity (26), and their alternative splicing can generate cell type–specific isoforms of key regulatory proteins that drive cellular differentiation (27, 28). Therefore, alteration of these exons could reprogram normal development into malignant transformation (29). Increasing evidence suggests that tissue-specific exons may achieve specificity in protein interactions, i.e., genes with such exons have interaction partners that are distinct in different tissues (23). Given the enrichment of genes containing tissue-specific exons for proteins with roles in signaling and development (23, 30), it is thus plausible that changes in such exons could rewire tissue-regulated interaction networks and signaling pathways from normal cellular function toward host tissue transformation.

Tissue-specific splicing has a determinative role in brain development (26, 31, 32). The brain is particularly rich in tissue-specific exons controlled by alternative splicing regulators critical to neuronal differentiation (23, 24, 30, 33, 34). The membrane-binding tumor suppressor ANXA7 (35, 36) belongs to a family of proteins involved in endosomal organization and function (37–40). ANXA7 contains a 66-bp alternative cassette exon (exon 6) that shows high prevalence in the brain, skeletal muscle, and heart (41, 42). The inclusion of this tissue-specific exon may be important for the function of the N-terminal domain of ANXA7 (42, 43), but its functional consequence is not well understood. Here, we define a role for lineage-specific splicing of a brain-enriched cassette exon in ANXA7 in the transforming deregulation of the EGFR oncoprotein during brain tumor progression. We show that the splicing is mediated by the heterogeneous nuclear ribonucleoprotein (hnRNP) polypyrimidine tract–binding protein 1 (PTBP1), an RNA-binding protein that is repressed during normal neurogenesis to allow the differentiation of progenitor cells into mature neurons (44, 45), but that is highly expressed in brain tumors (46, 47). Our observations illustrate the potential for context-specific splicing of a tissue-regulated alternative exon in a human tumor suppressor to eliminate its function and, by deregulating oncogenic signaling, contribute to tumor progression in the tissue of origin. Our findings also provide new evidence that the preexistence of lineage-specific traits in ancestral cells might augment genetic mechanisms to deregulate a common oncogene/tumor suppressor gene axis during human carcinogenesis.

Results

Lineage-specific splicing of a brain-enriched exon in ANXA7 abrogates EGFR regulation. To investigate the role of ANXA7 isoforms in brain tumorigenesis, we assessed alternative exon 6 exclusion by measuring the expression of ANXA7 isoform 1 (ANXA7-I1) and ANXA7-I2, which lacks exon 6, in normal brain, normal human astrocytes, neural precursor cells (NPCs), normal A2B5-positive or A2B5-negative glial progenitor cells (GPCs) (positive for nestin and glial fibrillary acid protein [GFAP] and negative for Sox1, Sox2, and the neuronal marker TuJ1), and glioblastoma (Figure 1A). We found abundant ANXA7-I1 mRNA and protein in normal brain (composed primarily of neurons), but very little of either in glioblastoma tissue or in patient-derived glioblastoma cultures, both of which showed high expression of ANXA7-I2 (Figure 1, B–D). Interestingly, we also noted abundant expression of ANXA7-I2 in astrocytes, NPCs, and GPCs (Figure 1B), suggesting that the patterned expression of this splice variant in the central nervous system is restricted to lineages that represent potential glioblastoma cells of origin (48).

EGFR signaling is repressed and dispensable in postmitotic, mature neurons (49, 50), but essential for the proliferation and maintenance of neural and glial precursor cells (51) — cell types that we found to primarily express spliced ANXA7-I2. These findings and our previous observation associating ANXA7 with deregulation of EGFR signaling in glioblastoma (2, 8) prompted further investigation of the differential functional roles of the 2 ANXA7 splice variants in EGFR regulation. SNB19 glioblastoma
cells were infected with lentivirus so as to overexpress empty control vector (EV), ANXA7-I2, or ANXA7-I1 and were stimulated with EGF ligand in a time-dependent fashion. ANXA7-I1 reexpression, but not ANXA7-I2 overexpression, resulted in sustained reduction in EGFR protein and phosphorylation and diminished activation of v-akt murine thymoma viral oncogene homolog (AKT) and extracellular signal–regulated kinase 1 and 2 (ERK1/2) (Figure 1E and Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI68836DS1).

Given the involvement of annexin family proteins in membrane scaffolding and vesicle trafficking (37–40), we hypothesized that ANXA7-I1 may affect EGFR trafficking and signal termination. Signaling through the EGFR receptor is spatiotemporally regulated by progression through the endocytic pathway, which involves targeting and sorting of the receptor into endosomes for degradation (52). Early endosomes, characterized by the early endosome antigen 1 (EEA1), give rise to multivesicular intermediates during transport toward late endosomes, characterized by the presence of the cation-dependent mannose-6-phosphate receptor (M6PR). We assessed the colocalization of EGFR with these early and late endosomal markers in the different lentivirally transduced cells (Figure 1F). Upon EGF stimulation, EGFR mostly colocalized with EEA1 and M6PR in cells reexpressing ANXA7-I1 (Figure 1F). In contrast, in control cells and in cells with ANXA7-I2 overexpression, we found that EGFR protein was widely dispersed throughout the cytoplasm (Figure 1F). These data suggest that ANXA7-I1, but not ANXA7-I2, efficiently targets EGFR for endosomal degradation. In accord with these findings, treatment with cycloheximide to halt new protein synthesis decreased the half-life of the EGFR receptor in ANXA7-I1–expressing cells, but not in control or ANXA7-I2–expressing cells (Figure 1, G and H).

PTBP1 mediates skipping of the alternative brain-specific exon in ANXA7 pre-RNA. Since in the brain, exon 6 is exclusively included in ANXA7 expressed in neurons, our data showing decreased exon 6 inclusion in glioblastoma could be due to the paucity of neuronal differentiation elements in the bulk tumor, except for the stem-like tumor fraction. Our finding that ANXA7-I2 is present in neural and astrocytic precursor cells suggests that this splice feature is inherited from these potential glioblastoma cells of origin and that this feature may be further exploited by the tumor cells to promote excessive EGFR signaling. Additionally, deregulation of splicing mechanisms in cancer-originating cells could also be involved. Abrupt splicing and exon deletions can result from mutations in alternative splice donor sites (53–55), or intronic single nucleotide polymorphisms have been associated with the increased production of alternatively spliced tumor suppressor transcripts that predispose to cancer (12). We therefore sequenced the brain-enriched exon 6 of the ANXA7 gene and parts of the flanking upstream and downstream intron/exon junctions harboring splicing sites in 35 human glioblastomas via conventional sequencing and pyrosequencing, but we found no sequence alterations that could explain the splicing of ANXA7 in these tumors (data not shown), further supporting the idea of inheritance of this lineage-specific splicing mechanism from a potential tumor-initiating ancestral cell.

To further address the mechanisms of splicing of the neuron-specific, EGFR-regulatory ANXA7 exon in these tumors, we identified 3 putative splicing factors among genes differentially expressed in glioblastomas (56): 2 promoters of exon inclusion downregulated in glioblastoma, RNA-binding protein, fox-1 homolog (C. elegans) 1 (RBFOX1) (57) and CUGBP, Elav-like family member 2 (CUGBP2) (58); and 1 promoter of exon exclusion upregulated in glioblastoma, the hnRNP PTBP1 (46, 47). We first confirmed the differential expression of these splicing factors in glioblastomas and glioblastoma-derived cell cultures (Figure 2A and Supplemental Figure 2, A–C), demonstrating low expression of RBFOX1 and CUGBP2 and high expression of PTBP1 in glioblastoma tumor and glioblastoma cultures compared with levels observed in normal brain. We then modulated the expression of each factor to test its potential role in ANXA7 splicing. Lentiviral overexpression of RBFOX1 or CUGBP2 did not alter expression of the 2 ANXA7 variants (Supplemental Figure 2, D–G). By contrast, lentiviral knockdown of PTBP1 via shRNAs in SNB19 and LN229 glioblastoma cells and in a primary brain tumor stem cell line (BTSC23), each of which expresses high levels of PTBP1 and lacks endogenous ANXA7-I1 expression, prompted the reexpression of the ANXA7-I1 transcript and protein compared with cells infected with scrambled, nontargeting shRNA (Figure 2, B–E, and Supplemental Figure 3, A–C). In turn, we observed that lentiviral overexpression of PTBP1 in a primary BTSC characterized by low endogenous PTBP1 expression (BTSC145) markedly decreased ANXA7-I1 expression (Figure 2F and Supplemental Figure 3D). These results are consistent with previous findings showing regulation of ANXA7 splicing by PTBP1 in HeLa cells (59–61).

We used RNA immunoprecipitation to test whether PTBP1 directly binds ANXA7 pre-RNA in glioblastomas. IP of PTBP1 efficiently coprecipitated ANXA7 RNA in the glioblastoma-derived cell line MB003, confirming a direct interaction (Figure 2, G and H). We further investigated the interaction between PTBP1 and the ANXA7 transcript during the splicing event using exon trapping. We cloned a minigene containing the genomic ANXA7 region from exon 5 to exon 7 (ANXA7E5-7) into a splicing reporter construct (ExonTrap) that allows monitoring of the splicing of an exogenous DNA sequence in vitro. We transfected SNB19 control (shCtrl) or PTBP1-knockdown (shPTBP1) cells with empty ExonTrap (ET) or ANXA7E5-7-ExonTrap (ET-ANXA7) vectors. PCR using primers specific for the ectopic genomic fragment identified the spliced exon in SNB19-shPTBP1-ET-ANXA7 cells, but not in SNB19-shCtrl-ET-ANXA7 cells, confirming a direct role of PTBP1 in ANXA7 exon 6 skipping and the importance of exon 6 neighboring introns in PTBP1-ANXA7 pre-RNA complexing (Figure 2I).

To confirm the agency of PTBP1 in ANXA7 exon 6 skipping, we sought PTBP1 binding sites on the ANXA7 minigene by analyzing cross-linking IP sequencing (CLIP-seq) data (61) on genome-wide PTB-RNA interactions and introducing mutations to specifically suppress PTBP1 binding to these regions (62). We created a binding model and trained it to extract 10 high-scoring binding-site candidates downstream, within, and upstream of exon 6 (Figure 2J). We introduced in silico binding-site mutations and identified sets of mutations that most significantly suppressed PTBP1 binding affinity (Figure 2J). We then used site-directed mutagenesis to assess the effect of 8 specific mutations on PTBP1 binding. Each mutation was tested for its ability to increase ANXA7-I1 expression after transfection of the mutated minigenes into SNB19 cells using the splicing reporter construct. All but 1 mutant increased ANXA7-I1 reexpression, confirming the repressive effect of the mutants on PTBP1 binding (Figure 2K). In agreement with our findings, a recent report suggests that multiple binding sites are involved in PTBP1-mediated silencing (60). To further confirm the role of PTBP1 in ANXA7 splicing regulation, we analyzed a data-
Figure 2
PTBP1 mediates exon 6 skipping in ANXA7 pre-RNA. (A) PTBP1 mRNA expression in normal brain, glioblastoma, and glioblastoma-derived lines by qRT-PCR. n = 8 (normal brain); n = 6 (glioblastoma tumors); n = 13 (glioblastoma-derived lines). Error bars represent the mean ± SD. (B) PTBP1, ANXA7-I1, and ANXA7-I2 protein abundance upon PTBP1 silencing in SNB19, LN229, and BTSC23 lines, the latter being run on a different gel (spliced blot is indicated by a thin black line). (C–F) qRT-PCR analysis showing changes in the ANXA7-I1/ANXA7-I2 mRNA ratio upon PTBP1 silencing in SNB19 (C), LN229 (D), and BTSC23 (E) lines (high endogenous PTBP1 expression) and upon PTBP1 overexpression in BTSC145 cells (low endogenous PTBP1 expression) (F). n = 3 independent experiments for all samples. Error bars represent the mean ± SD. (G and H) ANXA7 RNA IP with PTBP1 antibody in MB003 line. PTBP1 protein precipitation upon RNA IP (G). ANXA7 amplification from the anti-PTBP1 coprecipitated RNA fraction (H). (I) Splicing reporter (ET) assay after cloning ANXA7 genomic region from exon 5 to exon 7 showing reexpression of ANXA7-I1 in SNB19 shPTBP1-ET-ANXA7 cells. (J) Representation of the cloned ANXA7 minigene with predicted PTBP1-binding sites and RIP primer location. Heatmap based on PTB CLIP-seq data modeling showing the influence of individual nucleotide mutations 1–7 (superimposed); scores shown are from dark blue (positive) to white (negative); green represents midrange. Blue bars show PTB affinity to the original sequence (top) and the reduced PTB affinity of all 7 mutations (bottom). (K) Changes in ANXA7-I1/ANXA7-I2 mRNA ratio by qRT-PCR after mutagenesis in the cloned ANXA7 minigene. P values refer to each mutation versus wild-type. n = 3 independent experiments for all samples. Error bars represent the mean ± SD.
set that used next-generation systematic evolution of ligands by exponential enrichment (SELEX) to predict sequence and structural determinants of PTBP1 binding (63). Of note, 3 of the binding sites predicted in our analysis (M1, M2, and M5) overlapped with sites identified as PTBP1-binding motifs in ref. 63 and Supplemental Figure 3, E–G. We also analyzed a recently published dataset of genome-wide PTBP1 CLIP profiles after PTBP1 knockdown (64) in relation to \( \text{ANXA7} \) exons 5–7. Five of the sites selected for mutational analysis (M1, M2, M3, M4, and M8) also showed peaks in the CLIP analysis (Supplemental Figure 3H). Four of the other sites selected for site-directed mutagenesis were in regions of low mapability, indicating that these sites were missed by the CLIP analysis, given the lack of alignment with a unique position on the genome. Together, these results identify PTBP1 as the splicing factor that mediates skipping of alternative exon 6 in \( \text{ANXA7} \) and suggest a complex structure of PTBP1 binding to multiple sites in the intronic regions flanking the skipped exon.

**PTBP1 augments EGFR signaling through ANXA7 splicing.** Since PTBP1 mediates ANXA7 splicing and ANXA7-I1 regulates EGFR trafficking and signal termination, we assessed the direct effect of PTBP1 knockdown on EGFR signaling. SNB19-shPTBP1 cells had less EGFR protein abundance and less activating phosphorylation of EGFR, AKT, and ERK1/2 after EGF stimulation than did SNB19-shCtrl cells (Figure 3A). Immunostaining after 60 minutes of EGF stimulation showed EGFR scattered throughout the cytoplasm in SNB19-shCtrl cells, but condensed and colocalized with early and late endosomal markers EEA1 and M6PR in SNB19-shPTBP1 cells, suggesting its endosomal targeting and sorting for degradation (Figure 3B). The same results were obtained when SNB19 cells were transduced with a second shRNA sequence targeting PTBP1 (Supplemental Figure 4, A–D). Lentiviral double knockdown of PTBP1 and ANXA7-I1 in these cells (SNB19-shPTBP1-shANXA7-I1) reversed the endosomal targeting and restored EGFR and ERK1/2 activation (Figure 3, B–D).

For a more quantitative estimate of phosphorylated protein, we measured phosphorylated EGFR and ERK1/2 after EGF stimulation by probed isoelectric focusing (65) in PTBP1 and ANXA7-I1–single- and –double-knockdown cells. This analysis confirmed that PTBP1 silencing abrogates EGFR signaling and that concurrent ANXA7-I1 silencing rescues SNB19 cells from this effect (Supplemental Figure 5A–F). These results suggest that disinhibition of ANXA7-I1 regulation is the primary mechanism by which PTBP1 promotes EGFR signaling.

**PTBP1 knockdown inhibits glioblastoma malignancy and angiogenesis.** To further characterize the roles of PTBP1 and ANXA7 in a...
Figure 4
PTBP1 knockdown inhibits glioblastoma malignancy and angiogenesis. (A) Tumors resulting from intracranial injection of SNB19-shCtrl cells, SNB19-shPTBP1 cells, and SNB19-shPTBP1-shANXA7-I1–double-knockdown cells into the striatum of NOD/SCID mice (n = 8 animals per subgroup). The first 2 columns show representative H&E staining of tumor growth in 2 independent experiments; immunostaining by an antibody against human MMP9 (black and white signal at low magnification is shown in the third column, and red signal at higher magnification is shown in the fourth column) of representative tumors showing predominant intraparenchymal growth of SNB19-shCtrl tumors, predominant extraparenchymal growth of SNB19-shPTBP1 tumors, and partial reversal of the shPTBP1 phenotype by concurrent ANXA7-I1 knockdown. Scale bars: 1 mm (first 3 columns); 200 μm (fourth column). (B) Coimmunostaining for human vimentin and either EGFR or VEGF showing high abundance of both EGFR and VEGF in SNB19-shCtrl–derived tumors, low levels of EGFR and VEGF in SNB19-shPTBP1–derived tumors, and partial rescue of EGFR as well as VEGF expression in SNB19-shPTBP1-shANXA7-I1–derived tumors. Nuclei were counterstained with DAPI. Scale bar: 50 μm.
Figure 5

PTBP1 promotes angiogenesis in vivo. (A) H&E staining of representative tumors resulting from BTSC23 cells after lentiviral knockdown of PTBP1 (shPTBP1) or control knockdown with scrambled, nontargeting shRNA (shCtrl) and intracranial injection into the brains of NOD/SCID mice (first row); PTBP1 immunostaining showing complete loss of PTBP1 expression in shPTBP1 tumors (second row); immunostaining for angiogenesis markers PECAM1 and α-SMA showing loss of neangiogenesis in shPTBP1 tumors (third and fourth rows). Nuclei were counterstained with DAPI. Scale bar: 100 μm. (B) Quantification of the area occupied by blood vessels in the tumor samples described in A. n = 14 (shCtrl) and n = 12 (shPTBP1) independent samples. Error bars represent the mean ± SEM. (C) EC tube-formation assay. Quantification of the total length of the tubes observed in each well after a 24-hour incubation with medium conditioned (CM) by BTSC168 control cells (shC-shC), ANXA7-I1–knockdown cells (shC-shANXA7-I1), PTBP1-knockdown cells (shPTBP1-shC), or cells combining the 2 knockdowns (shPTBP1-shANXA7-I1). The measurements were taken under control conditions (no treatment) and upon erlotinib treatment. n = 9 independent samples. Error bars represent the mean ± SD.
mon pathway to glioblastoma progression, we overexpressed both ANXA7 variants with or without concurrent PTBP1 knockdown. SNB19-shPTBP1 and SNB19-shCtrl-ANXA7-11 cells were large, flat, and vacuolated, morphology reminiscent of senescent cells, while SNB19-shCtrl control cells and SNB19-shCtrl-ANXA7-12 cells were small and spindle shaped (Supplemental Figure 6A). SNB19 cells with PTBP1 knockdown expressed much more senescence-associated β-galactosidase than did cells without PTBP1 knockdown (Supplemental Figure 6C) and, consistent with a previous report, were less migratory and invasive (ref. 66 and Supplemental Figure 6, B and D–F).

To determine the effect of PTBP1 knockdown on brain tumor origenesis, we injected PTBP1-knockdown and control SNB19 cells into the striatum of immunocompromised NOD/SCID mice. SNB19 control cells produced invasive tumors with pseudopalisading necrosis, characteristic of glioblastoma (Figure 4A). By contrast, PTBP1-knockdown cells were found predominantly in the subarachnoid space, despite intraparenchymal injection confirmed by MRI (Figure 4A and Supplemental Figure 7A). Tumors originating from cells with PTBP1-ANXA7-11 double knockdown grew in both the striatum and the subarachnoid space (Figure 4A and Supplemental Figure 7A), suggesting that concurrent silencing of ANXA7-11 partially restored the invasive phenotype. Immunostaining for human MMP9, involved in extracellular matrix breakdown during invasion (67), strongly labeled tumor cells in satellites (Figure 4A), small, finger-shaped perivascular clusters associated with inhibition of neovascularization and the consequent co-option of preexisting host blood vessels (68, 69). Satellites were found in tumors from PTBP1-knockdown cells and in the extraparenchymal, subarachnoid portion of tumors from PTBP1-ANXA7-11–double-knockdown cells, but not in control tumors or in the invasive portion of striatal tumors from PTBP1-ANXA7-11–double-knockdown cells (Figure 4A). In accord with these observations, inhibition of glioma angiogenesis not only fosters growth of tumor cells in satellite structures along brain vessels, but also their migration over long distances to the subarachnoid space (68, 69).

**PTBP1 promotes tumor angiogenesis through modulation of ANXA7 and EGFR.** To verify that PTBP1 knockdown inhibits neoangiogenesis, we assessed the expression of VEGF, a major EGFR-regulated angiogenic factor in glioblastoma (70–74), and EGFR in the SNB19-derived tumors. Consistent with our in vitro observations, silencing of PTBP1 was associated with loss of EGFR expression in these tumors, and concurrent silencing of ANXA7-11 restored EGFR levels (Figure 4B and Supplemental Figure 7, B and C), confirming the role of ANXA7-11 in EGFR regulation. Moreover, VEGF was abundantly expressed in tumors derived from SNB19-shCtrl cells, but not in those derived from SNB19-shPTBP1 cells (Figure 4B and Supplemental Figure 7, B and C). VEGF expression in the tumors was partially restored by PTBP1-ANXA7-11 double knockdown, evidencing the role of a PTBP1/ANXA7/EGFR signaling axis in glioblastoma angiogenesis (Figure 4B and Supplemental Figure 7, B and C).

We then injected patient-derived BTSCs with high endogenous PTBP1 expression (BTSC23; amplified PTBP1 copy number variation in 537 TCGA glioblastomas) into the striatum of NOD/SCID mice. Control tumors, but not those from PTBP1-knockdown cells, had extensive pseudopalisading necrosis and diffuse hemorrhage (Figure 5A and Supplemental Figure 8A). Glioblastoma stem cells have been shown to generate new vessels in which ECs express the EC marker PECAM1 (aka CD31) (75), and vascular pericytes express the pericyte marker α-SMA (76) to support vessel function and tumor growth. Consistently, we found that control tumors abundantly expressed PECAM1 and α-SMA and had large, entangled vessels following tortuous paths (Figure 5, A and B). Conversely, PTBP1-knockdown tumors lacked PTBP1 expression and had sparse, small vessels and a paucity of endothelial and pericyte markers (Figure 5, A and B).

To further study the suggested role of PTBP1 in brain tumor angiogenesis, we correlated expression of PTBP1 with expression of genes involved in angiogenesis in 550 glioblastomas of The Cancer Genome Atlas (TCGA) project. We found significant coexpression of PTBP1 and multiple angiogenesis genes, many of which were also coexpressed with EGFR (Supplemental Figure 8B and Supplemental Table 1). TaqMan array analysis of angiogenesis genes in PTBP1-amplified BTSC23 cells after knockdown of PTBP1 (Supplemental Table 1) revealed an overlap between genes differentially expressed after PTBP1 knockdown and those coregulated with both PTBP1 and EGFR in the in silico analysis (Supplemental Table 1).

This finding and previous reports suggesting a role of EGFR in brain tumor angiogenesis (74, 77, 78) prompted further investigation of the differential expression of 7 EGFR-regulated angiogenesis genes (VEGF, ITGAV, CXCL10, LYVE1, COL15A1, CTGF, PDGFRA) after knockdown of PTBP1 in BTSC23 cells (high endogenous PTBP1) and after reexpression of PTBP1 in BTSC145 cells (low endogenous PTBP1). Real-time PCR demonstrated that PTBP1 knockdown reduced the expression of these genes in BTSC23 cells and that PTBP1 reexpression induced their expression in BTSC145 cells (Supplemental Figure 8, C and D).

We used an EC tube–formation assay to further evaluate the role of PTBP1 and ANXA7 in angiogenesis. This assay measures the ability of ECs, plated at subconfluent densities with the appropriate extracellular matrix support, to form capillary-like structures (aka tubes) (79). The addition of conditioned medium from BTSCs (BTSC168) with PTBP1 silencing markedly reduced the tube formation compared with that observed in the control group (Figure 5C and Supplemental Figure 8, E and F). By contrast, conditioned medium from BTSCs with isolated ANXA7-11 silencing did not affect tube formation, a finding reminiscent of the fact that given the high PTBP1 expression in these cells, there is virtually no endogenous ANXA7-11 expression and that PTBP1 needs to be silenced first to induce ANXA7-11. Consistently, conditioned medium from BTSCs with PTBP1-ANXA7-11 double knockdown induced tube formation that was not significantly different from that of the control group, suggesting a determining role of ANXA7 splicing in PTBP1-mediated angiogenesis (Figure 5C and Supplemental Figure 8, E and F). Intriguingly, conditioned medium from BTSCs treated with erlotinib to prevent EGFR activation further reduced total tube length and obscured the rescuing effect of concurrent ANXA7-11 knockdown (and thus EGFR disinhibition) on tube formation (Figure 5C). Bevacizumab treatment to block VEGF signaling had an effect on tube formation that was similar to that of erlotinib treatment in this angiogenesis model (Supplemental Figure 8G). Together, these data establish that the proangiogenic effect of PTBP1 involves a signaling axis from PTBP1 to altered ANXA7 splicing to EGFR deregulation.

**Gene amplification and loss of a neuron-specific microRNA deregulate PTBP1 in glioblastomas.** We examined the potential mechanisms of PTBP1 overexpression in glioblastomas. Our estimation of PTBP1 copy number variation in 537 TCGA glioblastomas found
the PTBP1 gene locus on chromosome 19p13.3 to be amplified in 34.6% of tumors (Figure 6A). Amplification of PTBP1 was associated with significantly increased PTBP1 expression in 428 patients with the combined availability of copy number and gene expression data (Figure 6C). However, many tumors had overexpression of the PTBP1 transcript (Figure 6A) and protein (Figure 6B) without gene amplification. Neuron-specific microRNA miR-124, which plays an important role in neurogenesis (80) and is repressed in high-grade gliomas (81–83) to enhance stem-like traits and invasiveness (84), directly targets PTBP1 during nervous system development (44). Our analysis of miR-124 expression in a panel of patient-derived BTSCs revealed consistently lower levels of miR-124 in glioblastoma-derived BTSCs and tumor cell cultures than were seen in normal brain and, in turn, showed higher levels of PTBP1 expression in the BTSCs and tumor cultures (Figure 6D). We found a highly significant inverse correlation between miR-124 and PTBP1 expression in 428 TCGA glioblastomas, although these tumors represented crude tissue samples that showed a high degree of cellular heterogeneity (Figure 6E). PTBP1 gene dosage and miR-124 expression remained significantly associated with PTBP1 expression in a multiple regression model in 355 glioblastomas, suggesting an independent contribution to increased PTBP1 expression in glioblastomas (Figure 6F). Of note, miR-124 expression levels were also lower and PTBP1 expression levels higher in NPCs and GPCs compared with those in normal brain. This further supports the idea that a common miR-124/PTBP1/ANXA7 splicing axis is inherited by glioblastoma cells from a potential ancestral precursor cell and that this axis is further exploited and constitutively activated during glioblastoma progression through the selection of additional genetic alterations, including PTBP1 amplification and, as we have shown before, heterozygous ANXA7 losses and EGFR aberrations (2, 8).

miR-124 has been shown to directly target PTBP1 mRNA during nervous system development and to thus promote neuronal differentiation (44). To confirm the regulation of PTBP1 by miR-124 in glioblastomas and to further verify the involvement of PTBP1 in ANXA7 splicing and EGFR regulation, we transfected SNB19 cells with double-stranded RNA oligonucleotides corresponding to the mature sequence of miR-124. miR-124 reexpression caused PTBP1 mRNA and protein downregulation, an increase in ANXA7/11 expression, and a decrease in ANXA7/12 expression (Figure 7, A–C). As a consequence, EGFR protein levels and phosphorylation decreased, consistent with its sorting to early and late endosomes, as evidenced by colocalization with early and late endosomal markers EEA1 and M6PR (Figure 7, D and E). We observed that control cells demonstrated a flattened morphology with large lamellipodia, while miR-124–expressing cells had a more elongated, almost neuron-like morphology with clear cellular bodies (Figure 7E). These findings suggest that loss of miR-124 is directly involved in the deregulation of PTBP1 and ensuing disinhibition of EGFR signaling through ANXA7 splicing in glioblastomas.

PTBP1 and EGFR have similar effects on clinical outcome. Finally, we assessed the association of PTBP1 expression and clinical outcome. Patients with high PTBP1 expression had significantly shorter survival than patients with low PTBP1 expression (hazard ratio [HR] for death with high versus low PTBP1 expression, 1.27; 95% CI, 1.02–1.58; \( P = 0.029 \) by the Cox model). This association was even more significant in newly diagnosed patients uniformly treated with chemoradiation (HR, 1.6; 95% CI, 1.18–2.18; \( P = 0.003 \) by the Cox model) (Figure 8A). Amplification of the EGFR oncogene and impaired signal termination both contribute to constitutive activation of EGFR in glioblastomas (5, 7); our results suggest that the latter mechanism includes PTBP1–mediated ANXA7 splicing. To gauge the relative clinical importance of PTBP1–mediated deregulation of EGFR and amplification of EGFR, we stratified patients into 4 subgroups, according to whether their tumors carried or lacked EGFR amplifications and whether they overexpressed PTBP1. Patients whose tumors overexpressed PTBP1 had outcomes similar to those of patients whose tumors harbored EGFR amplifications (\( P = 0.05 \) by the Cox model) (Figure 8B). These outcomes were worse than those of patients whose tumors had low PTBP1 expression and lacked EGFR amplification (HR for death with high PTBP1/wild-type EGFR vs. low PTBP1/wild-type EGFR, 2.04; 95% CI, 1.27–3.29; \( P = 0.003 \) by the Cox model, and HR for death with low PTBP1/EGFR amplification vs. low PTBP1/wild-type EGFR, 1.86; 95% CI, 1.15–3.00, \( P = 0.011 \) (Figure 8B). The concurrent presence of high PTBP1 expression and EGFR amplification did not portend a poorer prognosis than the isolated presence of either event in patients (\( P > 0.05 \) by the Cox model), supporting the notion that EGFR is the primary target of the oncogenic effect of PTBP1 in glioblastomas (Figure 8B). Furthermore, tumors with high PTBP1 expression had significantly lower EGFR mRNA levels than did tumors carrying EGFR amplifications, supporting our notion that PTBP1 upregulates EGFR at the protein level by inhibiting ANXA7–mediated EGFR degradation and not at the transcriptional level (Figure 8C). These data suggest that PTBP1 activation in glioblastoma produces a tumor phenotype biologically and clinically similar to that arising from EGFR amplification.

Discussion

We describe what we believe to be a novel mechanism of oncogenic pathway activation during brain tumor progression: lin-
Differential inclusion of tissue-specific exons usually does not interrupt the frame of translation (86), but can impact protein interactions (23). The spliced, alternative exon in ANXA7 may encode determinants for the interaction of ANXA7 with the endocytosis machinery. Consistently, we show that lack of this exon in glioblastoma leads to incomplete endosomal sorting and degradation of EGFR. Identification of a role of ANXA7 in endosomal targeting reinforces prior evidence that implicates other annexins in endosomal organization and function (38–40). Our observation that a tissue-specific exon can have a determining role on the function of a protein involved in endocytosis is also consistent with a recent report showing that a neural-specific alternative exon promotes an interaction between the nucleocytoplasmic adaptor protein bridging integrator 1 (Bin1) and brain-enriched amphiphysin II and the GTPase dynamin 2 (Dnm2) that facilitates endocytosis in neural cells (24).

Our study has identified PTBP1 as the primary mediator of ANXA7 exon skipping in brain tumors. Genome-wide mapping of PTBP1-RNA interactions has demonstrated that dominant PTB

differential-specific splicing of an alternative exon in a tumor suppressor that regulates an oncogenic pathway, eliminates the tumor suppressor’s function, and contributes to tumor progression. This mechanism is consistent with prior evidence that aberrant activation of EGFR cooperates with loss of tumor suppressor gene functions in the formation of glioblastomas and other tumors (85). In gliomagenesis, known synergy between the loss of tumor suppression and the aberrant activation of EGFR has been limited to the frequent co-occurrence of EGFR mutations and inactivating mutations of key tumor suppressors such as INK4A/ARF and PTEN (4, 85). In PTEN, such mutations impair EGFR degradation and signal termination (7). Signaling through EGFR is spatiotemporally regulated by its progression through the endocytotic pathway, which determines the receptor’s half-life and accessibility to signaling proteins and phosphatases (52). Our novel finding that ANXA7 splicing in glioblastoma reduces endosomal sorting of EGFR, leading to its downstream signal termination, establishes that the reduction of tumor suppressor gene regulation of EGFR signaling can also occur post-transcriptionally.

Figure 7
miR-124 regulates PTBP1 expression and its downstream effects on ANXA7 splicing and EGFR signaling. (A–C) qRT-PCR analysis showing changes in PTBP1 (A), ANXA7-I2 (B), and ANXA7-I1 (C) mRNA upon transfection of SNB19 cells with double-stranded RNA oligonucleotides corresponding to the mature sequence of miR-124. (D) Immunoblot analysis showing the expression of PTBP1, ANXA7-I1, ANXA7-I2, phospho-EGFR, and total EGFR in EGF-stimulated SNB19 cells transfected as in A. (E) Early (EEA1) and late (M6PR) endosomal marker communostaining with EGFR in EGF-stimulated SNB19 cells infected as in A. Nuclei were counterstained with DAPI. Scale bars: 50 μm; 10 μm (inset).
binding near a competing constitutive splice site generally induces exon inclusion, whereas prevalent binding close to an alternative site often causes exon skipping (61), as we show here for ANXA7.

In contrast, a recent study (60) demonstrated that PTBP1 binding upstream or within a cassette exon acts as a repressor; instead, when bound only on the downstream intron, it mediates exon inclusion. Our site-directed mutagenesis of in silico–predicted PTBP1-binding sites slightly differs from what was described in these previous studies, suggesting a more complex binding model, in which several possible binding motifs located within, as well as upstream and downstream of, the exon cooperatively contribute to the splicing of the alternative cassette exon according to their affinity to PTBP1. Consistent with this model, the analysis of PTBP1-mediated ANXA7 exon 6 splicing by Llorian and colleagues shows that a splicing reporter construct containing mutations of putative PTB binding sites in the exon remains responsive to PTBP1 knockdown, suggesting the presence of additional PTBP1 binding sites (60).

In the brain, PTBP1 expression is restricted to non-neuronal lineages such as astrocytes and neural progenitors (45), which we further confirmed for A2B5-positive and A2B5-negative glial progenitor cells (87, 88). We found that PTBP1 was highly expressed in glioblastomas through downregulation of miRNA-124. Moreover, we show that amplification of the PTBP1 gene represents an additional mechanism to deregulate PTBP1 in glioblastomas. These findings are consistent with the proposed role of stem-like cells as potential glioblastoma cells of origin (89–91). We found that silencing of PTBP1 attenuated both glioblastoma malignancy and angiogenesis in tumors from BTSCs, despite their high native propensity to generate tumor endothelium (75, 92) or, as more recently suggested, to generate vascular pericytes to support tumor growth (76). Consistent with our proposed role for PTBP1 in angiogenesis, PTBP1 was identified as a gene upregulated in laser-capture microdissected glioblastoma vessels compared with that seen in nonmalignant human brain tissue, suggesting its role as a vascular tumor marker (93). In our SNB19 xenograft model, PTBP1 silencing results in the formation of cell satellites around vessel cores and in concomitant tumor cells spreading in the subarachnoid space. This phenotype is reminiscent of tumor growth in mice treated with VEGF inhibitor (69) or upon VEGF knockdown (68). The distinct tumor phenotype observed in the SNB19 xenograft model could be due to the fact that SNB19-derived tumors form less vessels when grown orthotopically than do BTSC-derived tumors. Strikingly, concurrent silencing of ANXA7-I1 restored the control group tumor phenotype, suggesting that the effect of PTBP1 on tumor angiogenesis is, at least in part, mediated by ANXA7-I1 deregulation. This hypothesis is also supported by the rescuing effect of ANXA7-I1 knockdown over the inhibition exerted by PTBP1 silencing on the ability of ECs to form capillary-like structures. Given our proposed role of ANXA7-I1 as a regulator of EGFR trafficking, it is plausible that EGFR plays a major role in the observed phenotype. The putative role of EGFR in this process finds further confirmation in the inhibitory effect of erlotinib treatment on tube formation and in the fact that many EGFR target genes with roles in angiogenesis are also regulated by PTBP1. Nonetheless, further studies will be necessary to fully reveal the mechanism by which PTBP1 regulates vessel formation.

Mapping of PTBP1 in a chromosomal region, 19p13.3, which is frequently amplified in glioblastomas (2), further supports its oncogenic function. Our finding that EGFR amplification and PTBP1 overexpression portend a similarly poor clinical outcome highlights the importance of PTBP1-mediated activation of EGFR. It is currently understood that EGFR signaling is repressed and dispensable in postmitotic, mature neurons (49, 50), which express EGFR signal-terminating ANXA7-I1. Conversely, EGFR signaling is essential for the proliferation and maintenance of neural and glial precursors (51); these cells are highly enriched for ANXA7-I2, which lacks EGFR-regulatory capabilities. This suggests that the EGFR pathway–activating splicing trait peculiar to glioblastoma cells might be inherited from these progenitor lineages, which may represent the potential cell of origin of glioblastoma (48). Therefore, it is likely that the mir-124/PTBP1/ANXA7 splicing axis is not a tumor-specific, but rather a lineage-specific, characteristic that is further exploited to promote tumor progression through the accumulation and selection of additional genetic alterations, including PTBP1 amplification, heterozygous ANXA7 deletion, and EGFR aberrations (2, 8). Altogether, these genetic alterations cumulatively contribute to the establishment of a permissive environment by enhancing EGFR pathway activation.

Some support for the conservation of a “normal-like” function of a common miR-124/PTBP1 axis in glioblastomas comes from our observation that restoration of mir-124 expression in glioblastoma cells induces a more neuron-like morphology. The role of miR-124 in neuronal differentiation is well documented (44): RE1 silencing transcription factor (REST) controls miR-124 disinhibition, driving the differentiation of neural progenitor cells into mature neurons by directly targeting PTBP1 mRNA (44, 94). Consequently, it is reasonable to conclude that PTBP1 downregulation upon miR-124 restoration in glioblastoma cells is not just a side effect of these cells undergoing neuronal differentiation, but rather a driving force that promotes the switch to a neuron-like phenotype. Of note, neuronal differentiation is associated with accumulation of the nervous system–enriched and PTBP1-repressed paralog PTBP2 (44, 45). Cross-regulation and functional redundancy have been reported for both paralogs (59), yet a functional role for PTBP2 in ANXA7 splicing and EGFR regulation remains to be defined. Recent genome-wide and high-throughput analyses of a PTBP2-controlled splicing regulatory program have shown PTBP2 to target a large set of cassette exons, but not alternative exon 6 of ANXA7 (95, 96), suggesting that this PTBP1 paralog lacks potential EGFR-regulatory capability through modulation of ANXA7 splicing.

Collectively, our paradigm of malignant progression consequent to the lineage-specific splicing of a tissue-regulated, alternative exon in a tumor suppressor and the ensuing oncoprotein activation, which we have elucidated in glioblastoma, may have widespread applicability in explaining how changes in tissue-specific, post-transcriptional regulatory mechanisms can contribute to reprogramming of normal development into oncogenesis.

**Methods**

An expanded Methods section is provided in the Supplemental Methods.

**Clinical samples, glioblastoma cell lines, and lentiviral infection.** Tumor samples were collected under IRB-approved guidelines and with informed patient consent at Stanford University, Northwestern University, Cleveland Clinic, and the University of Freiburg. Primary BTSCs were grown in neurobasal media supplemented with EGF, FGF2, and LIF. Glioblastoma cell lines, HEK 293T, and Phoenix cells were grown in DMEM with 10% FBS. For overexpression and silencing experiments, glioblastoma cells and primary BTSCs were infected with lentiviral particles generated by cotransfection of lentiviral plasmids with pCMV-MD2G and psPAX2 vectors in HEK 293T.

**Isolation, culture, sorting, and characterization of normal glial progenitor cells.** Normal glial progenitor cells were derived from resected primary patient tissue
following neurosurgery. Tissue was dissociated, and cells with the ability to proliferate were selected for culture over 2 passages. Proliferative cells were then sorted for A2B5 using anti-A2B5 MicroBeads (Miltenyi Biotec) and characterized for nestin (Rat-401, 1:200; Developmental Studies Hybridoma Bank [DSHB]), GFAP (20334, 1:5,000; Dako), Sox1 (AF3369, 1:200; R&D Systems), Sox2 (AF2018, 1:100; R&D Systems), and neuronal Tuj1 (MAB1195, 1:500; R&D Systems) expression by immunofluorescence staining.

Mutational analysis. Exon 6 of the ANXA7 gene and parts of the flanking upstream and downstream intron/exon junctions harboring splicing sites were sequenced in 35 human glioblastoma samples via conventional sequencing on a 3730 DNA Analyzer (Applied Biosystems) and via pyrosequencing on a PyroMark Q96 MD System (Qiagen).

Quantitative real-time PCR. Quantitative RT-PCR (qRT-PCR) was performed via TaqMan Assay (Applied Biosystems) or SYBR green (Applied Biosystems). Expression of angiogenesis markers was detected using a TaqMan Human Angiogenesis Array (Applied Biosystems). The primers used for qRT-PCR are listed in Supplemental Table 2.

PTBP1–binding site prediction and mutagenesis. PTBP1 binding sites were predicted using PTB-CLIP-seq data (61, 64) and next-generation SELEX (63) as previously described (62). Mutagenesis was performed using the QuikChange II Site-Directed Mutagenesis kit (Agilent Technologies). The primers used for mutagenesis are listed in Supplemental Table 3.

RNA IP. RNA IP was performed in SNB19 cells using the RiboCluster Profiler RIP-Assay Kit (MBL International).

Migration, invasion, and senescence assays. For the wound-healing assay, SNB19-infected cells were grown at 95% confluence. A scratch of approximately 1 mm was made, and images were taken every 24 hours using an Axiovert wide-field microscope (Zeiss). A BioCoat Matrigel Invasion Chamber (BD Biosciences) was used for Matrigel invasion assays according to the manufacturer’s instructions. Cellular senescence was assessed via β-galactosidase labeling as measured with a Senescence Detection kit (Calbiochem).

Intracranial injection. Six- to 8-week-old NOD/SCID mice (Charles River Laboratories) were intracranially injected with BTSC23 or SNB19 cells stably expressing firefly luciferase and infected with lentivirus as described earlier (97). Bioluminescence imaging was performed using the Xenogen in vivo imaging system.

Endothelial cell tube formation assay. HUVECs (Millipore) were seeded in Matrigel-covered 24-well plates at a concentration of 80,000 cells per
well and incubated for 24 hours with 500 µl of complete neurobasal medium conditioned by BTSCs with various knockdown genotypes for the previous 48 hours (79).

Statistics. Linear regression analyses and graphical model validation were executed using R software. Scatter plots and locally weighted least-squares (LOWESS) smooths were used to confirm the suitability of linear regression analyses, and statistical significance of these relationships was assessed according to the P value for the estimated slope of the regression line. A multiple linear regression model was computed based on the ordinary least-squares method. Survival curves were estimated by the Kaplan-Meier product-limit method, and survival distributions were compared across groups using the log-rank test or by Cox proportional hazards model. An unpaired t test and Wilcoxon’s rank-sum test were used as appropriate. P values less than 0.05 were considered significant, except for linear regression analysis of regressed expression of PTBP1 and EGFR with multiple angiogenesis genes, in which a false discovery rate–adjusted q value less than 0.001 was considered significant.

Study approval. Human studies were approved by the IRBs of Stanford University, Northwestern University, and Cleveland Clinic and by the ethics committee of the University of Freiburg. Animal studies were approved by the animal review committee of the University of Freiburg.

Acknowledgments

This study was supported by National Cancer Institute grant P20 CA151129-01/A1, UAB Specialized Program of Research Excellence (SPORE) in Brain Cancer; a Mike Gardner/American Brain Tumor Association Grant; the National Brain Tumor Society; a German Cancer Aid Grant Award (107714); a Project Award of Accelerate Brain Cancer Cure, Illinois Excellence in Academic Medicine Program Award (211); and State of Alabama Investment Pool for Action (IMPACT) funds. We thank Maria Oberle for help with mice brain histology; M. Lübbert for providing access to the pyrosequencing facility; T. Feuerstein for normal brain tissues; M. Machain for providing HUVECs and input on the tube formation assay; C. Haas for access to microscopy equipment (all University of Freiburg); A. Krainer for the pWZL-FLAG-Box1 plasmid (Cold Spring Harbor Laboratory); K. Xu for the pCDNA-FLAG-CUGBP2 plasmid (University of Georgia); and V. Baezelandt for the pLV-eGFP lentivector virus (Katholieke Universiteit Leuven).

Received for publication December 3, 2013, and accepted in revised form April 3, 2014.

Address correspondence to Markus Bredel, Department of Radiation Oncology, University of Alabama at Birmingham, Hazelrig-Salter Radiation Oncology Center, Rm. 2220A, 1700 6th Avenue South, Birmingham, Alabama 35233, USA. Phone: 205.934.5199; Fax: 205.970.9443; E-mail: mbredel@uab.edu. Or to: Maria S. Carro, Department of Neurosurgery, University of Freiburg, Breisacher Str. 64, D-79106 Freiburg, Germany. Phone: 011.49.761.270.54400; Fax: 011.49.761.270.54470; E-mail: maria.carro@uniklinik-freiburg.de.

4. McLendon R, Friedman A, Bigner DD, Van Meir EG. The phosphatase and tensin homolog (SPORE) in Brain Cancer; a Mike Gardner/American Brain Medicine Program Award (211); and State of Alabama Investment Pool for Action (IMPACT) funds. We thank Maria Oberle for help with mice brain histology; M. Lübbert for providing access to the pyrosequencing facility; T. Feuerstein for normal brain tissues; M. Machain for providing HUVECs and input on the tube formation assay; C. Haas for access to microscopy equipment (all University of Freiburg); A. Krainer for the pWZL-FLAG-Box1 plasmid (Cold Spring Harbor Laboratory); K. Xu for the pCDNA-FLAG-CUGBP2 plasmid (University of Georgia); and V. Baezelandt for the pLV-eGFP lentivector virus (Katholieke Universiteit Leuven).

Received for publication December 3, 2013, and accepted in revised form April 3, 2014.

Address correspondence to Markus Bredel, Department of Radiation Oncology, University of Alabama at Birmingham, Hazelrig-Salter Radiation Oncology Center, Rm. 2220A, 1700 6th Avenue South, Birmingham, Alabama 35233, USA. Phone: 205.934.5199; Fax: 205.970.9443; E-mail: mbredel@uab.edu. Or to: Maria S. Carro, Department of Neurosurgery, University of Freiburg, Breisacher Str. 64, D-79106 Freiburg, Germany. Phone: 011.49.761.270.54400; Fax: 011.49.761.270.54470; E-mail: maria.carro@uniklinik-freiburg.de.

4. McLendon R, Friedman A, Bigner DD, Van Meir EG. The phosphatase and tensin homolog (SPORE) in Brain Cancer; a Mike Gardner/American Brain Medicine Program Award (211); and State of Alabama Investment Pool for Action (IMPACT) funds. We thank Maria Oberle for help with mice brain histology; M. Lübbert for providing access to the pyrosequencing facility; T. Feuerstein for normal brain tissues; M. Machain for providing HUVECs and input on the tube formation assay; C. Haas for access to microscopy equipment (all University of Freiburg); A. Krainer for the pWZL-FLAG-Box1 plasmid (Cold Spring Harbor Laboratory); K. Xu for the pCDNA-FLAG-CUGBP2 plasmid (University of Georgia); and V. Baezelandt for the pLV-eGFP lentivector virus (Katholieke Universiteit Leuven).

Received for publication December 3, 2013, and accepted in revised form April 3, 2014.

Address correspondence to Markus Bredel, Department of Radiation Oncology, University of Alabama at Birmingham, Hazelrig-Salter Radiation Oncology Center, Rm. 2220A, 1700 6th Avenue South, Birmingham, Alabama 35233, USA. Phone: 205.934.5199; Fax: 205.970.9443; E-mail: mbredel@uab.edu. Or to: Maria S. Carro, Department of Neurosurgery, University of Freiburg, Breisacher Str. 64, D-79106 Freiburg, Germany. Phone: 011.49.761.270.54400; Fax: 011.49.761.270.54470; E-mail: maria.carro@uniklinik-freiburg.de.
57. Zhang C, et al. Defining the regulatory network of
54. Woolfe A, Mullikin JC, Elnitski L. Genomic features
51. Aguirre A, Rubio ME, Gallo V. Notch and EGFR
50. Wagner B, Natarajan A, Grunaug S, Kroismayr R,
41. Rick M, Ramos Garrido SI, Herr C, Thal DR,
40. White IJ, Bailey LM, Aghakhani MR, Moss SE,
2876
72. Cheng SY, et al. Suppression of glioblastoma angio-
73. Pore N, Liu S, Haas-Kogan DA, O'Rourke DM,
71. Goldman CK, Kim J, Wong WL, King V, Brock T,
69. Kunkel P, et al. Inhibition of glioma angiogenesis
68. Lu KV, et al. VEGF inhibits tumor cell invasion and
66. Cheung HC, et al. Splicing factors PTBP1 and
65. O'Neill RA, et al. Isoelectric focusing technology
64. Xue Y, et al. Direct conversion of fibroblasts to neu-
63. Kiel AT, et al. The expression of the splicing regula-
62. Llorian M, et al. Position-dependent alternative splic-
60. Llorian M, et al. Position-dependent alternative splic-
59. Noegel AA, Clemen CS. Nuclear localization of
58. Bonavia R, et al. EGFRvIII promotes glioma angio-
57. Zhang C, et al. Defining the regulatory network of
54. Woolfe A, Mullikin JC, Elnitski L. Genomic features
51. Aguirre A, Rubio ME, Gallo V. Notch and EGFR
50. Wagner B, Natarajan A, Grunaug S, Kroismayr R,
41. Rick M, Ramos Garrido SI, Herr C, Thal DR,
40. White IJ, Bailey LM, Aghakhani MR, Moss SE,
2876
72. Cheng SY, et al. Suppression of glioblastoma angio-
73. Pore N, Liu S, Haas-Kogan DA, O'Rourke DM,
71. Goldman CK, Kim J, Wong WL, King V, Brock T,
69. Kunkel P, et al. Inhibition of glioma angiogenesis
68. Lu KV, et al. VEGF inhibits tumor cell invasion and
66. Cheung HC, et al. Splicing factors PTBP1 and
65. O'Neill RA, et al. Isoelectric focusing technology
64. Xue Y, et al. Direct conversion of fibroblasts to neu-
63. Kiel AT, et al. The expression of the splicing regula-
62. Llorian M, et al. Position-dependent alternative splic-
60. Llorian M, et al. Position-dependent alternative splic-
59. Noegel AA, Clemen CS. Nuclear localization of
58. Bonavia R, et al. EGFRvIII promotes glioma angio-
57. Zhang C, et al. Defining the regulatory network of
54. Woolfe A, Mullikin JC, Elnitski L. Genomic features
51. Aguirre A, Rubio ME, Gallo V. Notch and EGFR
50. Wagner B, Natarajan A, Grunaug S, Kroismayr R,
41. Rick M, Ramos Garrido SI, Herr C, Thal DR,
40. White IJ, Bailey LM, Aghakhani MR, Moss SE,